The inaugural European Society of Cardiology (ESC) Guideline on cardio-oncology, revealed at the ESC Congress 2022 in Barcelona, Spain, provides some much-needed information on the concurrent management of cancer and cardiovascular (CV) disease.
A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Timing of antihypertensive medication intake, be it in the morning or evening, does not appear to affect the risk of cardiovascular death or hospitalization for non-fatal myocardial infarction (MI) or non-fatal stroke, according to results of the TIME trial presented at ESC 2022.
Compared with aspirin alone, treatment with a P2Y12 inhibitor (clopidogrel or ticagrelor) is associated with lower risks of cardiovascular (CV) death, myocardial infarction (MI), or stroke in patients with established coronary artery disease (CAD), according to the PANTHER* trial presented at ESC 2022.
Older adults who receive a high-dose quadrivalent influenza vaccine have a 49 percent reduced risk of death and a 64 percent reduced risk of hospitalization for influenza or pneumonia compared with those who receive a standard-dose vaccine, results of the DANFLU-1 study showed.
Early, long-term lipid lowering with the PCSK9 inhibitor evolocumab further reduces cardiovascular (CV) events, including CV death, without any safety signal, in the FOURIER* open-label extension (OLE) study.
Adding the oral factor XIa (FXIa) inhibitor asundexian to dual antiplatelet therapy (DAPT) may be a safe and effective oral anticoagulation (OAC) alternative for acute MI patients, findings from the PACIFIC-AMI study suggest.
A polypill comprising aspirin, ramipril, and atorvastatin, significantly reduced the incidence of major adverse cardiovascular (CV) events in patents with a recent myocardial infarction (MI), according to results of a phase III trial presented at ESC 2022.